The efficacy and peripheral blood predictors in recurrent platinum-resistant ovarian cancer patients treated with immune checkpoint inhibitors

Baoyue Pan, Xiaojing Zheng, Yongwen Huang, Wei Wei, Shije Xu, Siyu Chen, Jiaxin Yin, Yu Zhang, Jundong Li, Min ZhengJournal of Ovarian Research 2025 · DOI

Abstract

This study investigates the efficacy of immune checkpoint inhibitors (ICIs) in combination therapies for patients with recurrent, platinum-resistant ovarian cancer (PROC). Results show a promising 36.6% objective response rate. Additionally, the research identifies specific peripheral blood markers, including C-reactive protein (CRP) and inflammatory cytokines such as MCP-1 and TNF-α, as independent predictors of patient survival and progression-free survival.

Introduction

Ovarian cancer remains a significant clinical challenge due to its aggressive nature and high recurrence rate. Approximately 80% of patients experience recurrence, often developing "platinum resistance," where standard chemotherapy becomes ineffective. While immune checkpoint inhibitors (ICIs) have revolutionized the treatment of various malignancies, their efficacy as monotherapy in ovarian cancer has been limited, with response rates typically between 6% and 15%. This study addresses the need for improved combination strategies and reliable biomarkers to identify patients most likely to benefit from these therapies.

Methods

The researchers conducted a retrospective analysis of 71 PROC patients treated at the Sun Yat-sen University Cancer Center between 2017 and 2022. Most patients received ICIs in combination with chemotherapy or anti-angiogenic agents.

A key technical component of the study was the use of a 13-plex cytokine assay. Serum concentrations of 13 inflammatory cytokines were measured using a flow-cytometry-based LEGENDplex kit. The team also performed immunohistochemistry (IHC) on available tumor samples to assess CD8+ T-cell infiltration and PD-L1 expression (Combined Positive Score). Statistical modeling, including Cox regression, was used to identify independent predictors of Overall Survival (OS) and Progression-Free Survival (PFS).

Flow cytometry gating strategy and cytokine analysis used to measure serum inflammatory markers in PROC patients.

Results and Discussion

Clinical Efficacy and the "Platinum Re-sensitization" Phenomenon

The study reported an Objective Response Rate (ORR) of 36.62% and a Disease Control Rate (DCR) of 78.87%. These figures are notably higher than historical rates for ICI monotherapy, suggesting that combination regimens may effectively prime the tumor microenvironment. Interestingly, patients who progressed after immunotherapy and returned to platinum-based chemotherapy showed a partial response rate of 55.55%, suggesting that ICIs might re-sensitize tumors to traditional agents.

Prognostic Biomarkers in Peripheral Blood

The analysis identified several critical blood-based markers:

  • Overall Survival (OS): The median OS was 15.37 months. High baseline C-reactive protein (CRP > 10 mg/L), a marker of systemic inflammation, was the strongest independent risk factor for shorter OS.
  • Progression-Free Survival (PFS): Multivariate analysis identified four independent predictors of longer PFS: age over 55 years, low LDL-C levels, low TNF-α, and high MCP-1.

These findings highlight the role of the systemic inflammatory environment in determining the success of immunotherapy. High levels of MCP-1, which recruits immune cells, and low levels of the inflammatory cytokine TNF-α were particularly significant for progression-free outcomes.

Conclusion

This research demonstrates that ICI combination therapies are a viable option for platinum-resistant ovarian cancer. The identification of peripheral blood cytokines and CRP as prognostic markers provides a non-invasive method for patient stratification. While the study is limited by its retrospective nature and sample size, it lays the groundwork for future prospective trials to validate these biomarkers as a predictive panel for clinical use.

Summary updated

Abstract

Not applicable.
BibTeX
@article{pan2025efficacy,
  author = {Baoyue Pan and Xiaojing Zheng and Yongwen Huang and Wei Wei and Shije Xu and Siyu Chen and Jiaxin Yin and Yu Zhang and Jundong Li and Min Zheng},
  title = {{The efficacy and peripheral blood predictors in recurrent platinum-resistant ovarian cancer patients treated with immune checkpoint inhibitors}},
  journal = {Journal of Ovarian Research},
  year = {2025},
  doi = {10.1186/s13048-025-01755-7},
}
Figure